HomeStock ScreenerCorona Remedies

Corona Remedies Current Share Price | Corona Remedies Stock Screener

CORONA Pharmaceuticals
Live Share Price NSE
₹2121.40
▲ 2.00 (0.09%)
2026-08-19 00:00:00
Live Share Price BSE
₹2123.85
▲ 9.05 (0.43%)
2026-08-19 00:00:00
As of August 19, 2026, the live Corona Remedies share price (NSE: CORONA) is ₹2,121.40 on NSE and ₹2,123.85 on BSE, up 0.09% from the previous close, with shares trading between ₹2,107.10 and ₹2,160.50 in today's trading session, and a 52-week range of ₹1,347.70–₹2,159.70. Analyse CORONA share price charts and track historical price performance. Use the Corona Remedies stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Corona Remedies Market Cap ₹12,965.33 Cr.
CORONA P/E Ratio (TTM) 64.99
Corona Remedies P/B Ratio 17.32
EPS (TTM) ₹30.27
Dividend Yield 0.47%
Debt to Equity 0.19
CORONA 52 Week High ₹2159.70
Corona Remedies 52 Week Low ₹1347.70
Operating Margin 22.00%
Profit Margin 14.08%
CORONA Revenue (TTM) ₹426.00
EBITDA ₹96.00
Net Income ₹60.00
Total Assets ₹1,205.00
Total Equity ₹747.00

Corona Remedies Current Share Price Chart

Track the current Corona Remedies share price and stock price with an interactive chart. Analyse CORONA price trends, trading volume, historical performance, and volatility across different timeframes — the complete Corona Remedies stock quote in one place.

Corona Remedies Company Profile - Fundamental Screener

Screen Corona Remedies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CORONA shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE02ZQ01018

Corona Remedies Balance Sheet Screener

Screen CORONA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2026 2025 2024 2023
Assets
Total Assets 1,205 930 831 595
Current Assets 348 339 290 292
Fixed Assets 554 370 384 185
Liabilities
Total Liabilities 0 0 0 0
Current Liabilities 97 84 126 49
Non-Current Liabilities 0 0 0 0
Shareholders' Equity
Total Equity 747 606 480 409
Share Capital 61 61 61 61
Reserves & Surplus 686 545 419 347

Corona Remedies Income Statement Screener - Profit & Revenue Analysis

Screen Corona Remedies income statement and profit fundamentals. Analyze CORONA quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Corona Remedies share price evaluation.
Item 2026-Jun 2026-Mar 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Jun 2024-Sept 2024-Dec
Revenue 426 358 295 349 364 345 293 316 299
Expenses 329 291 240 277 283 278 242 247 228
EBITDA 96 66 56 72 81 66 51 69 70
Operating Profit % 22.00% 18.00% 18.00% 20.00% 22.00% 19.00% 17.00% 21.00% 23.00%
Depreciation 13 10 10 9 9 9 8 9 10
Interest 3 1 2 2 2 2 3 3 2
Profit Before Tax 80 55 44 61 70 55 39 57 58
Tax 20 9 12 15 18 14 9 14 13
Net Profit 60 45 32 46 52 41 30 43 45
EPS 9.83 7.41 5.16 7.55 8.55 6.75 4.90 7.03 7.35

Corona Remedies Cash Flow Screener - Liquidity Fundamentals

Screen CORONA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2026-March 2025-March 2024-March 2023-March
Operating Activities 230 191 157 103
Investing Activities -256 -84 -267 -50
Financing Activities 25 -107 99 -45
Net Cash Flow -1 0 -11 8

Corona Remedies Shareholding Pattern Screener

See Corona Remedies shareholding pattern with promoter, FII, and DII holdings. Check Corona Remedies promoter holding and ownership changes for CORONA on TickJournal.
Item 2026-Jun 2026-Mar 2025-Dec 2025-Apr
Promoter Holding 69.00% 69.00% 69.00% 72.50%
FII Holding 3.63% 2.25% 1.84% 0.00%
DII Holding 12.90% 7.02% 6.76% 0.00%
Govt Holding 0.00% 0.00% 0.00% 0.00%
Public Holding 0.89% 0.77% 1.36% 0.00%
Other Holding 13.58% 20.97% 21.05% 27.50%
Shareholder Count 20,185 19,609 9 9

Corona Remedies Share Dividend Screener - Share Yield Analysis

Check Corona Remedies dividend history with payout and yield data. View Corona Remedies dividend details including ex-dates and amounts for CORONA stock.
Period Dividend Per Share Dividend Yield
2026-March ₹10.00 0.47%
2025-March ₹7.31 0.47%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Corona Remedies Stock Index Membership

See which indices include Corona Remedies stock. Check CORONA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Corona Remedies is not part of any tracked indices.
Only major market indices are tracked in our system.

Corona Remedies Market Events Screener - Corporate Actions

Get Corona Remedies corporate actions including splits, bonuses, and buybacks. Check Corona Remedies stock events that may affect CORONA share price.
Announcement Date Record Date Event Type Information Price Impact
2026-07-31 2026-07-31 Quarterly Result Announcement NA 1.27%
2026-07-09 2026-07-09 Annual General Meeting NA 14.52%
2026-06-19 2026-06-19 Dividend ₹ 10.00 /share 7.04%
2026-05-11 2026-05-11 Quarterly Result Announcement NA 1.36%
2026-02-02 2026-02-02 Quarterly Result Announcement NA 3.06%
2026-01-02 2026-01-02 Quarterly Result Announcement NA 4.10%

Corona Remedies Competitors Screener - Peer Comparison

Screen CORONA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 453,594 37.16 61,674 12.69% 11,565 33.60
Divis Laboratories 227,108 78.05 11,067 13.95% 2,568 74.07
Torrent Pharmaceuticals 188,986 87.77 13,886 20.34% 2,138 54.91
Cipla 115,498 34.47 29,045 2.24% 3,870 44.38
Zydus Life Science 112,920 24.26 27,658 17.64% 5,026 46.32
Lupin 101,780 18.33 29,039 26.75% 5,356 32.17
Mankind Pharma 99,532 47.74 14,636 14.85% 1,938 38.61
Dr Reddys Laboratories 98,700 30.95 35,059 3.90% 4,158 43.27
Laurus Labs 97,530 89.91 6,868 22.01% 890 64.93
Aurobindo Pharma 94,270 25.64 34,145 5.56% 3,503 59.26

Corona Remedies Company Announcements - News Screener

Screen CORONA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-08-12 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-08-12 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-03 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-08-01 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-31 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-07-31 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-07-31 Unaudited Financial Results For The First Quarter And Three Months Ended June 30 2026 -
2026-07-31 Board Meeting Outcome for Outcome Of Board Meeting -
2026-07-22 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-07-17 Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results On Standalone And Consolidated Basis For First Quarter And Three Months Ended June 30 2026 -
2026-07-10 Shareholders Meeting / Postal Ballot- Scrutinizers Report -
2026-07-09 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-07-06 Compliances-Certificate Under Reg. 74(5) Of SEBI (DP) Regulations 2018 -
2026-06-30 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-06-30 Commencement Of Commercial Production -
2026-06-29 Closure of Trading Window -
2026-06-19 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-06-19 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-06-19 Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 -
2026-06-19 Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 -